For people with atrial fibrillation (Afib or AF), stopping oral anticoagulation (OAC) after a "successful" catheter ablation ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...

C, shares how she saved Dr Jacquelyn Lacera’s life from a near-fatal cardiovascular event while aboard a flight from Hawaii.

These patients were generally older and more likely to have atrial fibrillation (AFib), advanced heart failure ... distinguishing between ventricular functional TR (VFTR), caused by right ...

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a challenge for Milestone Pharmaceutical in its 22 years. | The FDA has rejected ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...

The drug is also under study for atrial fibrillation with rapid ventricular rate (AFib-RVR). As of December 31, 2024, Milestone Pharmaceuticals reported having $69.7 million in cash, cash ...

Milestone (WA: MMD )’s President and CEO, Joe Oliveto, expressed the company’s disappointment with the CRL but reaffirmed their commitment to CARDAMYST as a potential novel treatment for PSVT. The ...

The symptoms of ventricular tachycardia are similar to those of AFib and include palpitations ... Compared to atrial fibrillation, VT packs a much bigger cardiac punch. “In terms of risk ...